by Alex Bajjon | Jul 1, 2020 | Briefings, UK
Background Regeneron owned two patents relating to transgenic mice that produce hybrid antibodies containing human variable regions and mouse constant regions. More specifically, the claimed mice contain an in situ replacement at a murine chromosomal immunoglobulin...
by Sean Hughes | May 1, 2020 | Briefings, EPO
Background In T 1063/18 (Peppers), the Board held that Rule 28(2) EPC should be disregarded, and that plants produced by essentially biological processes should be considered patentable. Specifically, the Board found that the EPO Administrative Council’s...
by Alex Bajjon | Apr 1, 2020 | Briefings, US & International
Genentech owns US Patents 7,846,441 and 7,892,549 which both relate to treating cancers characterised by overexpression of the ErbB2 receptor (which includes breast cancers). The claims of these two patents relate to treating a human patient with a combination of an...
by Carolyn Haywood | Mar 1, 2020 | Briefings, US & International
Earlier this month, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its judgement in Illumina, Inc. v. Ariosa Diagnostics, Inc. and if the judgement stands, it may offer diagnostic companies a new way of navigating 35 U.S.C. § 101 – by way of...
by Alex Bajjon | Mar 1, 2020 | Briefings, EPO
In this case, the Technical Board of Appeal has confirmed that claims directed to new uses of known non-medical products may be patentable and have clarified the approach that should be taken when assessing the novelty of such claims. Claim 1 of EP 1 865 998 is for...
Recent Comments